Supplemental material
Open access
7,484
Views
14
CrossRef citations to date
0
Altmetric
Review
The evolution of cyclin dependent kinase inhibitors in the treatment of cancer
Komal Jhaveria Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA;b Weill Cornell Medical College, New York, NY, USACorrespondence[email protected]
View further author information
, View further author information
Howard A Burris 3rdc Department of Investigational Cancer Therapeutics, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USAView further author information
, Timothy A Yapd Department of Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, USAView further author information
, Erika Hamiltonc Department of Investigational Cancer Therapeutics, Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN, USAView further author information
, Hope S Rugoe Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USAView further author information
, Jonathan W Goldmanf David Geffen School of Medicine at UCLA, Los Angeles, CAView further author information
, Stephen Danng Pfizer Inc., New York, NY, USAView further author information
, Feng Liug Pfizer Inc., New York, NY, USAView further author information
, Gilbert Y Wongg Pfizer Inc., New York, NY, USAView further author information
, Heike Krupkag Pfizer Inc., New York, NY, USAView further author information
& Geoffrey I Shapiroh Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USAView further author information
show all
Pages 1105-1124
|
Received 11 Feb 2021, Accepted 07 Jun 2021, Published online: 01 Sep 2021
Related research
People also read lists articles that other readers of this article have read.
Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.
Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.